Oryzon Genomics — Making headway rolling into H225
Oryzon Genomics has reported its Q225 results, summarising an active period. Its programme focused on vafidemstat in borderline personality...
174 Views
Oryzon Genomics — KOL event highlights vafidemstat potential in BPD
At Oryzon Genomics’ key opinion leader (KOL) event, vafidemstat’s path through Phase III in borderline personality disorder (BPD) was laid out. The...
431 Views
Oryzon Genomics — A step closer to a new treatment paradigm in BPD
Oryzon Genomics has submitted the Phase III clinical trial protocol to the FDA for its lysine-specific demethylase 1 (LSD1) inhibitor, vafidemstat,...
253 Views
Oryzon Genomics — Preparations in place for an active 2025
Q125 saw Oryzon make significant headway towards Phase III for vafidemstat in BPD and clinical advancement for iadademstat across multiple...
255 Views
Oryzon Genomics — €13.3m grant improves operating headroom
Oryzon Genomics has been awarded a €13.26m (US$15m) non-dilutive grant under the Med4Cure initiative, part of the Important Project of Common...
308 Views